CAMBRIDGE, Mass. - Scholar Rock (NASDAQ: SRRK), a biopharmaceutical company valued at $3.82 billion, is progressing towards the commercialization of apitegromab, a potential treatment for spinal muscular atrophy (SMA). The company, whose stock has surged over 414% in the past six months, is on track to submit regulatory applications in the first quarter of 2025, with a U.S. launch anticipated in the fourth quarter of the same year. InvestingPro analysis reveals 12 additional investment insights for SRRK, including key metrics on profitability and growth potential.
Apitegromab, a muscle-targeted therapy, is in late-stage development for SMA, a rare neuromuscular disorder. The company aims to expand its use into other rare neuromuscular conditions, leveraging its selective anti-myostatin approach.
In addition to SMA, Scholar Rock is advancing its cardiometabolic program, with topline data from the Phase 2 EMBRAZE trial in obesity expected in the second quarter of 2025. The trial is evaluating apitegromab in combination with a GLP-1 receptor agonist. Another candidate, SRK-439, also targeting myostatin, is on track for an Investigational New Drug (IND) application filing in the third quarter of 2025 for obesity treatment.
The company's strategic priorities for 2025 include the commercialization of apitegromab for SMA, expanding the potential benefits of apitegromab, and advancing the anti-myostatin program in cardiometabolic disorders.
Scholar Rock has also initiated the Phase 2 OPAL clinical trial for SMA patients under two years old, set to begin in mid-2025. This follows the positive results from the pivotal Phase 3 SAPPHIRE trial, which met its primary endpoint in improving motor function in SMA patients.
The company's financial position is robust, with sufficient funds to support operations and capital expenditure requirements into the fourth quarter of 2026. According to InvestingPro data, Scholar Rock maintains a healthy current ratio of 3.88, indicating strong liquidity, while operating with moderate debt levels. Analyst price targets range from $33 to $57, reflecting varied expectations for the company's growth potential. Scholar Rock's management will present further updates at the 43rd Annual J.P. Morgan Healthcare Conference. For comprehensive analysis, investors can access the detailed Pro Research Report, available exclusively on InvestingPro, covering this and 1,400+ other top US stocks.
Apitegromab has received Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the FDA, as well as PRIME and Orphan Medicinal Product designations from the EMA for the treatment of SMA. However, apitegromab has not been approved for any use by the FDA or any other regulatory agency.
The information presented in this article is based on a press release statement.
In other recent news, Scholar Rock has been the subject of multiple analyst upgrades following significant developments in its drug trials. H.C. Wainwright increased its price target for Scholar Rock to $50.00, maintaining a Buy rating, following the announcement of Biohaven's failed Phase 3 RESILIENT study of taldefgrobep alfa for Spinal Muscular Atrophy (SMA). This adjustment was based on the anticipated market performance and potential of Scholar Rock's apitegromab.
Truist Securities also raised its price target for the company to $45.00 after a competitor's SMA drug failed in Phase 3 trials. The firm increased its peak sales estimate for Apitegromab to $1.5 billion, reflecting a belief that the SMA market opportunity may be larger than previously expected.
BMO Capital Markets adjusted its price target for Scholar Rock to $39.00, maintaining an Outperform rating. The firm highlighted the company's third-quarter earnings and the positive results from its Phase 3 SAPPHIRE study for apitegromab.
These recent developments highlight Scholar Rock's consistent efforts to address unmet needs in the medical field, with a U.S. commercial launch of Apitegromab planned for Q4 2025 and the initiation of a placebo-controlled Phase 2 obesity trial expected towards the end of 2024.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.